Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
